Sac-TMT alone or with pembrolizumab for advanced triple-negative breast cancer
Treatments studied
Part of Cancer, Skin clinical trials.
This trial tests a new drug, Sac-TMT, given alone or with an immunotherapy drug (pembrolizumab) for people with advanced triple-negative breast cancer who have not yet received any treatment for advanced disease. The goal is to see if this combination can shrink tumors or slow the cancer's growth.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have triple-negative breast cancer that has come back or spread and cannot be cured with surgery or radiation.
- You have not yet had any chemotherapy or other systemic treatment for your advanced breast cancer.
- If you had treatment for early-stage breast cancer, it must have completed at least 6 months before the cancer returned.
- You must be healthy enough to receive pembrolizumab and at least one of the standard chemotherapy options (paclitaxel, nab-paclitaxel, or gemcitabine with carboplatin).
- Any side effects from past cancer treatments must have mostly gone away (except for hair loss or skin color changes).
- You do not have active or uncontrolled infections, heart disease, lung disease, or other serious medical conditions.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study tests a new drug called Sacituzumab Tirumotecan (Sac-TMT) for people with early-stage, high-risk breast cancer that hasn't spread. The drug is given before surgery to see if it can shrink tumors and improve outcomes.
This trial tests a combination of two drugs—sacituzumab govitecan (a targeted therapy) and Q901 (a study drug that blocks a protein needed for cancer cell growth)—in people with advanced triple-negative breast cancer who have already tried other treatments. The goal is to see if this combination can shrink or control the cancer.
This trial tests a new combination of two drugs (sacituzumab tirumotecan and pembrolizumab) compared to standard chemotherapy for people with triple-negative breast cancer that did not fully respond to initial treatment. It aims to see if this combination helps prevent cancer from coming back.
This trial tests a new sequence of drugs (Sac-TMT followed by capecitabine) versus capecitabine alone for people with early-stage, high-risk triple-negative breast cancer who do not have BRCA mutations. It aims to see if the added treatment helps prevent the cancer from coming back.
This study tests a combination of two drugs—Sacituzumab Tirumotecan (Sac-TMT) and an immunotherapy called KL-A167—given before surgery to shrink triple-negative breast tumors. It aims to improve outcomes for people with early-stage, high-risk breast cancer who have not yet had any treatment.
This trial tests a combination of two drugs, sacituzumab govitecan (Sac-TMT) and toripalimab, as a first treatment for women with advanced triple-negative breast cancer that tests positive for a protein called PD-L1. The goal is to see if this combination is safe and effective in shrinking or controlling the cancer.
Hear when a new Triple Negative Breast Neoplasms trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.